Solid Biosciences (NASDAQ: SLDB) net income
Solid Biosciences reported a net loss of $174.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $124.7m. Earnings per share were −$1.99.
Solid Biosciences's best year of the last 9 was fiscal 2017. It reported a loss in 9 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$174.3m | — | — | −$1.99 |
| 2024 | −$124.7m | — | — | −$3.06 |
| 2023 | −$96.0m | — | — | −$4.83 |
| 2022 | −$86.0m | — | −1,062.3% | −$10.10 |
| 2021 | −$72.2m | — | −530.0% | −$10.14 |
| 2020 | −$88.3m | — | — | −$25.50 |
| 2019 | −$117.2m | — | — | — |
| 2018 | −$74.8m | — | — | — |
| 2017 | −$52.1m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Solid Biosciences net income compared with its sector
By net income for its latest fiscal year, Solid Biosciences ranks 399th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 397th | ARS Pharmaceuticals | −$171.3m | −203.3% |
| 398th | Armata Pharmaceuticals | −$173.8m | — |
| 399th | Solid Biosciences | −$174.3m | — |
| 400th | Zai Lab | −$175.5m | −38.1% |
| 401st | Celcuity | −$177.0m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Solid Biosciences
- How much did Solid Biosciences earn in fiscal 2025?
- Solid Biosciences reported a net loss of $174.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $124.7m.
- What are the earnings per share of Solid Biosciences?
- They were −$1.99 in fiscal 2025, compared with −$3.06 in fiscal 2024.
- Where does Solid Biosciences rank in its sector by net income?
- It ranks 399th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Solid Biosciences come from?
- From the annual report (Form 10-K) that Solid Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Solid Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Solid Biosciences: the Solid Biosciences page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.